Prevalence and predictors of potential drug-drug interactions

[1] Michalets E.L., Williams C.R., Drug interactions with cisapride: clinical implications, Clin. Pharmacokinet., 2000, 39, 49–75 http://dx.doi.org/10.2165/00003088-200039010-0000410.2165/00003088-200039010-00004Search in Google Scholar

[2] Juntti-Patinen L., Neuvonen P.J., Drug-related deaths in a university central hospital, Eur. J. Clin. Pharmacol., 2002, 58, 479–482 http://dx.doi.org/10.1007/s00228-002-0501-210.1007/s00228-002-0501-2Search in Google Scholar

[3] Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients, BMJ., 2004, 329, 15–19 http://dx.doi.org/10.1136/bmj.329.7456.1510.1136/bmj.329.7456.15Search in Google Scholar

[4] Zed P.J., Abu-Laban R.B., Balen R.M., Loewen P.S., Hohl C.M., Brubacher J.R., et al., Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study, CMAJ., 2008, 178, 1563–1569 http://dx.doi.org/10.1503/cmaj.07159410.1503/cmaj.071594Search in Google Scholar

[5] Patel P., Zed P.J., Drug-related visits to the emergency department: how big is the problem?, Pharmacotherapy, 2002, 22, 915–923 http://dx.doi.org/10.1592/phco.22.11.915.3363010.1592/phco.22.11.915.33630Search in Google Scholar

[6] Guédon-Moreau L., Ducrocq D., Duc M.F., Quieureux Y., L’Hôte C., Deligne J., et al., Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999, Eur. J. Clin. Pharmacol., 2003, 59, 689–695 http://dx.doi.org/10.1007/s00228-003-0684-110.1007/s00228-003-0684-1Search in Google Scholar

[7] Huang S.M., Lesko L.J., Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?, J. Clin. Pharmacol. 2004, 44, 559–569 http://dx.doi.org/10.1177/009127000426536710.1177/0091270004265367Search in Google Scholar

[8] Moura C.S., Acurcio F.A., Belo N.O., Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci., 2009, 12, 266–272 10.18433/J35C7ZSearch in Google Scholar

[9] Einarson T.R., Metge C.J., Iskedjian M., Mukherjee J., An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutarylcoenzyme A reductase inhibitors on health care utilization: a Canadian population-based study, Clin. Ther. 2002, 24, 2126–2136 http://dx.doi.org/10.1016/S0149-2918(02)80102-310.1016/S0149-2918(02)80102-3Search in Google Scholar

[10] Saurat J.H., Guérin A., Yu A.P., Latremouille-Viau D., Wu E.Q., Gupta S.R., et al., High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice, Dermatology, 2010, 220, 128–137 http://dx.doi.org/10.1159/00027519810.1159/000275198Search in Google Scholar PubMed

[11] Pergolizzi J.V. Jr., Labhsetwar S.A., Amy Puenpatom R., Ben-Joseph R., Ohsfeldt R., Summers K.H., Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids, Pain Pract., 2012, 12, 45–56 http://dx.doi.org/10.1111/j.1533-2500.2011.00503.x10.1111/j.1533-2500.2011.00503.xSearch in Google Scholar PubMed

[12] Pergolizzi J.V. Jr., Labhsetwar S.A., Puenpatom R.A., Ben-Joseph R., Ohsfeldt R., Summers K.H., Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids, Pain Pract., 2012, 12, 33–44 http://dx.doi.org/10.1111/j.1533-2500.2011.00498.x10.1111/j.1533-2500.2011.00498.xSearch in Google Scholar PubMed

[13] Hamilton R.A., Briceland L.L., Andritz M.H., Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population, Pharmacotherapy, 1998, 18, 1112–1120 Search in Google Scholar

[14] Obreli-Neto P.R., Nobili A., de Oliveira Baldoni A., Guidoni C.M., de Lyra Junior D.P., Pilger D., et al., Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study, Eur. J. Clin. Pharmacol., 2012, 68, 1667–1676 http://dx.doi.org/10.1007/s00228-012-1309-310.1007/s00228-012-1309-3Search in Google Scholar PubMed

[15] van Roon E.N., Flikweert S., le Comte M., Langendijk P.N., Kwee-Zuiderwijk W.J., Smits P., et al., Clinical relevance of drug-drug interactions: a structured assessment procedure, Drug Saf., 2005, 28, 1131–1139 http://dx.doi.org/10.2165/00002018-200528120-0000710.2165/00002018-200528120-00007Search in Google Scholar PubMed

[16] Tatro D.S., Drug Interaction Facts? 2012 — The authority on drug interactions, Facts and Comparasions, St. Louis, Wolters Kluwer Health, 2011 Search in Google Scholar

[17] Aparasu R., Baer R., Aparasu A., Clinically important potential drug-drug interactions in outpatient settings, Res. Social. Adm. Pharm., 2007, 3, 426–437 http://dx.doi.org/10.1016/j.sapharm.2006.12.00210.1016/j.sapharm.2006.12.002Search in Google Scholar PubMed

[18] Grönroos P.E., Irjala K.M., Huupponen R.K., Scheinin H., Forsström J., Forsström J.J., A medication database a tool for detecting drug interactions in hospital, Eur. J. Clin. Pharmacol., 1997, 53, 13–17 http://dx.doi.org/10.1007/s00228005033010.1007/s002280050330Search in Google Scholar PubMed

[19] Merlo J., Liedholm H., Lindblad U., Björck-Linné A., Fält J., Lindberg G., et al., Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study, BMJ., 2001, 323, 427–428 http://dx.doi.org/10.1136/bmj.323.7310.42710.1136/bmj.323.7310.427Search in Google Scholar PubMed PubMed Central

[20] Bergendal L., Friberg A., Schaffrath A., Potential drug-drug interactions in 5125 mostly elderly outpatients in Gothenburg, Sweden, Pharm. World Sci., 1995, 17, 152–157 http://dx.doi.org/10.1007/BF0187970910.1007/BF01879709Search in Google Scholar PubMed

[21] Costa A.J., Potential drug interactions in an ambulatory geriatric population, Fam. Pract., 1991, 8, 234–236 http://dx.doi.org/10.1093/fampra/8.3.23410.1093/fampra/8.3.234Search in Google Scholar PubMed

[22] Obreli Neto P.R., Nobili A., Marusic S., Pilger D., Guidoni C.M., Baldoni Ade O., et al., Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system, J. Pharm. Pharm. Sci., 2012, 15, 344–354 10.18433/J37K5WSearch in Google Scholar

[23] Björkman I.K., Fastbom J., Schmidt I.K., Bernsten C.B., Pharmaceutical Care of the Elderly in Europe Research (PEER) Group, Drug-drug interactions in the elderly, Ann. Pharmacother., 2002, 36, 1675–1681 http://dx.doi.org/10.1345/aph.1A48410.1345/aph.1A484Search in Google Scholar PubMed

[24] Janchawee B., Wongpoowarak W., Owatranporn T., Chongsuvivatwong V., Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand, J. Clin. Pharm. Ther., 2005, 30, 13–20 http://dx.doi.org/10.1111/j.1365-2710.2004.00598.x10.1111/j.1365-2710.2004.00598.xSearch in Google Scholar PubMed

[25] Cruciol-Souza J.M., Thomson J.C., Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital, J. Pharm. Pharm. Sci., 2006, 9, 427–433 Search in Google Scholar

[26] Doubova-Dubova S.V., Reyes-Morales H., Torres-Arreola Ldel P., Suárez-Ortega M., Potential drugdrug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City, BMC. Health Serv. Res., 2007, 7, 147 http://dx.doi.org/10.1186/1472-6963-7-14710.1186/1472-6963-7-147Search in Google Scholar PubMed PubMed Central

[27] Nobili A., Pasina L., Tettamanti M., Lucca U., Riva E., Marzona I., et al., Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database, J. Clin. Pharm. Ther., 2009, 34, 377–386 http://dx.doi.org/10.1111/j.1365-2710.2009.01021.x10.1111/j.1365-2710.2009.01021.xSearch in Google Scholar PubMed

[28] Lin C.F., Wang C.Y., Bai C.H., Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study, Drugs Aging, 2011, 28, 219–225 http://dx.doi.org/10.2165/11586870-000000000-0000010.2165/11586870-000000000-00000Search in Google Scholar PubMed

[29] Bjerrum L., Andersen M., Petersen G., Kragstrup J., Exposure to potential drug interactions in primaryhealth care, Scand. J. Prim. Health Care., 2003, 21, 153–158 http://dx.doi.org/10.1080/0281343031000180610.1080/02813430310001806Search in Google Scholar PubMed

[30] Johnell K., Klarin I., The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600000 elderly patients from the Swedish Prescribed Drug Register, Drug Saf., 2007, 30, 911–918 http://dx.doi.org/10.2165/00002018-200730100-0000910.2165/00002018-200730100-00009Search in Google Scholar PubMed

[31] Gagne J.J., Maio V., Rabinowitz C., Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy, J. Clin. Pharm. Ther., 2008, 33, 141–151 http://dx.doi.org/10.1111/j.1365-2710.2007.00891.x10.1111/j.1365-2710.2007.00891.xSearch in Google Scholar PubMed

[32] Janchawee B., Owatranporn T., Mahatthanatrakul W., Chongsuvivatwong V., Clinical drug interactions in outpatients of a university hospital in Thailand, J. Clin. Pharm. Ther., 2005, 30, 583–590 http://dx.doi.org/10.1111/j.1365-2710.2005.00688.x10.1111/j.1365-2710.2005.00688.xSearch in Google Scholar PubMed

[33] Carthy P., Harvey I., Brawn R., Watkins C., A study of factors associated with cost and variation in prescribing among GPs, Fam. Pract., 2000, 17, 36–41 http://dx.doi.org/10.1093/fampra/17.1.3610.1093/fampra/17.1.36Search in Google Scholar PubMed

[34] Rahmner P.B., Gustafsson L.L., Larsson J., Rosenqvist U., Tomson G., Holmström I., Variations in understanding the drug-prescribing process: a qualitative study among Swedish GPs, Fam. Pract., 2009, 26, 121–127 http://dx.doi.org/10.1093/fampra/cmn10310.1093/fampra/cmn103Search in Google Scholar

[35] Wun Y.T., Chan C.S., Dickinson J.A., Determinants of physicians’ attitude towards prescribing, J. Clin. Pharm. Ther., 2002; 27, 57–65 http://dx.doi.org/10.1046/j.1365-2710.2002.00389.x10.1046/j.1365-2710.2002.00389.xSearch in Google Scholar

[36] WHO Collaborating Centre for Family of International Classifications. International Classification of Diseases. Available from: http://www.who.int/classifications/icd/en/ Accessed: 2012 December Search in Google Scholar

[37] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available from: http://www.whocc.no/atc_ddd_index/ Accessed: 2012 December Search in Google Scholar

[38] Fulda T.R., Valuck R.J., Zanden J.V., Parker S., Byrns P.J., Disagreement among drug compendia on inclusion and ratings of drug-drug interactions, Curr. Ther. Res., 2000, 61, 540–548 http://dx.doi.org/10.1016/S0011-393X(00)80036-310.1016/S0011-393X(00)80036-3Search in Google Scholar

[39] Vitry A.I., Comparative assessment of four drug interaction compendia, Br. J. Clin. Pharmacol., 2007, 63, 709–714 http://dx.doi.org/10.1111/j.1365-2125.2006.02809.x10.1111/j.1365-2125.2006.02809.xSearch in Google Scholar

[40] Rätz-Bravo A.E., Tchambaz L., Krähenbühl-Melcher A., Hess L., Schlienger R.G., Krähenbühl S., Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy, Drug Saf., 2005, 28, 263–275 http://dx.doi.org/10.2165/00002018-200528030-0000710.2165/00002018-200528030-00007Search in Google Scholar

[41] Chatsisvili A., Sapounidis I., Pavlidou G., Zoumpouridou E., Karakousis V.A., Spanakis M., et al., Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece, Pharm. World Sci., 2010, 32, 187–193 http://dx.doi.org/10.1007/s11096-010-9365-110.1007/s11096-010-9365-1Search in Google Scholar

[42] Jones J.D., Mogali S., Comer S.D., Polydrug abuse: a review of opioid and benzodiazepine combination use, Drug Alcohol Depend., 2012, 125, 8–18 http://dx.doi.org/10.1016/j.drugalcdep.2012.07.00410.1016/j.drugalcdep.2012.07.004Search in Google Scholar

[43] Gelkopf M., Bleich A., Hayward R., Bodner G., Adelson M., Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic, Drug Alcohol Depend., 1999, 55, 63–68 http://dx.doi.org/10.1016/S0376-8716(98)00175-610.1016/S0376-8716(98)00175-6Search in Google Scholar

[44] Stitzer M.L., Griffiths R.R., McLellan A.T., Grabowski J., Hawthorne J.W., Diazepam use among methadone maintenance patients: patterns and dosages, Drug Alcohol Depend., 1981, 8, 189–199 http://dx.doi.org/10.1016/0376-8716(81)90061-210.1016/0376-8716(81)90061-2Search in Google Scholar

[45] Teixeira J.J., Crozatti M.T., dos Santos C.A., Romano-Lieber N.S., Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil, PloS One, 2012, 7, e47062 http://dx.doi.org/10.1371/journal.pone.004706210.1371/journal.pone.0047062Search in Google Scholar PubMed PubMed Central

[46] Secoli S.R., Figueras A., Lebrão M.L., de Lima F.D., Santos J.L., Risk of potential drug-drug interactions among Brazilian elderly: a populationbased, cross-sectional study, Drugs Aging, 2010, 27, 759–770 http://dx.doi.org/10.2165/11538460-000000000-0000010.2165/11538460-000000000-00000Search in Google Scholar PubMed

[47] Rosholm J.U., Bjerrum L., Hallas J., Worm J., Gram L.F., Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study, Dan. Med. Bull., 1998, 45, 210–213 Search in Google Scholar

[48] Hohl C.M., Dankoff J., Colacone A., Afilalo M., Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department, Ann. Emerg. Med., 2001, 38, 666–671 http://dx.doi.org/10.1067/mem.2001.11945610.1067/mem.2001.119456Search in Google Scholar PubMed

[49] Rambhade S., Chakarborty A., Shrivastava A., Patil U.K., Rambhade A., A survey on polypharmacy and use of inappropriate medications, Toxicol. Int., 2012, 19, 68–73 http://dx.doi.org/10.4103/0971-6580.9450610.4103/0971-6580.94506Search in Google Scholar PubMed PubMed Central

[50] Reason B., Terner M., Moses McKeag A., Tipper B., Webster G., The impact of polypharmacy on the health of Canadian seniors, Fam. Pact., 2012, 29, 427–432 http://dx.doi.org/10.1093/fampra/cmr12410.1093/fampra/cmr124Search in Google Scholar PubMed

[51] Veehof L.J., Stewart R.E., Meyboom-de Jong B., Haaijer-Ruskamp F.M., Adverse drug reactions and polypharmacy in the elderly in general practice, Eur. J. Clin. Pharmacol., 1999, 55, 533–536 http://dx.doi.org/10.1007/s00228005066910.1007/s002280050669Search in Google Scholar PubMed

[52] Lopez-Picazo J.J., Ruiz J.C., Sanchez J.F., Ariza A., Aguilera B., Lazaro D., et al., Prevalence and typology of potential drug interactions occuring in primary care patients, Eur. J. Gen. Pract., 2010, 16, 92–99 http://dx.doi.org/10.3109/13814788.2010.48170910.3109/13814788.2010.481709Search in Google Scholar PubMed

[53] Sloan R.W., Drug interactions, Am. Fam. Physician, 1983, 27, 229–238 Search in Google Scholar